Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome | Zendy

Gerilyn M. Olsen | Zendy; Leanna M. Hansen | Zendy; Nicole S. Stefanko | Zendy; Erin F. Mathes | Zendy; Katherine B. Püttgen | Zendy; Megha M. Tollefson | Zendy; Christine T. Lauren | Zendy; Anthony J. Mancini | Zendy; Catherine McCuaïg | Zendy; Ilona J. Frieden | Zendy; Denise M. Adams | Zendy; Eulàlia Baselga | Zendy; Sarah L. Chamlin | Zendy; Deepti Gupta | Zendy; Peter C. Frommelt | Zendy; Maria C. Garzón | Zendy; Kimberly A. Horii | Zendy; Justyna Klajn | Zendy; Mohit Maheshwari | Zendy; Brandon Newell | Zendy; Henry Nguyen | Zendy; Amy J. Nopper | Zendy; Julie Powell | Zendy; Dawn H. Siegel | Zendy; Beth A. Drolet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluating the Safety of Oral Propranolol Therapy in Patients With PHACE Syndrome

Author(s) -

Gerilyn M. Olsen,

Leanna M. Hansen,

Nicole S. Stefanko,

Erin F. Mathes,

Katherine B. Püttgen,

Megha M. Tollefson,

Christine T. Lauren,

Anthony J. Mancini,

Catherine McCuaïg,

Ilona J. Frieden,

Denise M. Adams,

Eulàlia Baselga,

Sarah L. Chamlin,

Deepti Gupta,

Peter C. Frommelt,

Maria C. Garzón,

Kimberly A. Horii,

Justyna Klajn,

Mohit Maheshwari,

Brandon Newell,

Henry Nguyen,

Amy J. Nopper,

Julie Powell,

Dawn H. Siegel,

Beth A. Drolet

Publication year - 2019

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2019.3839

Subject(s) - medicine , propranolol , adverse effect , retrospective cohort study , infantile hemangioma , hemangioma , stroke (engine) , common terminology criteria for adverse events , incidence (geometry) , pediatrics , surgery , mechanical engineering , physics , optics , engineering

Oral propranolol is widely considered to be first-line therapy for complicated infantile hemangioma, but its use in patients with PHACE (posterior fossa malformations, hemangioma, arterial anomalies, cardiac defects, eye anomalies) syndrome has been debated owing to concerns that the cardiovascular effects of the drug may increase the risk for arterial ischemic stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research